Mallinckrodt Teams up with UK RNAi Biotech in Deal Worth up to €553M

The UK-based biotech Silence Therapeutics has signed a deal worth up to €553M ($693M) with the UK pharma company Mallinckrodt to develop RNA interference (RNAi) therapies for autoimmune diseases. Mallinckrodt will pay Silence Therapeutics €17.8M...

This Biotech Breaks Down ‘Undruggable’ Proteins to Treat Cancer

In the Polish city of Wrocław, Captor Therapeutics is developing cancer treatments that destroy disease-causing proteins. Mission: To develop cancer treatments able to degrade proteins that are normally outside the reach of traditional drugs, called...

Link between diabetes and heart failure stronger in women than men

Researchers from The George Institute for Global Health determined that this differential was greater in type 1 than type 2 diabetes. Type 1 diabetes is associated with a 47% excess risk of heart failure...

Omega-6 fatty acid could help prevent heart disease

An omega-6 polyunsaturated fatty acid has the potential to help fight heart disease, finds a new study by researchers at Cardiff University in collaboration with Ben-Gurion University of the Negev. With funding from the British...

Acute and short-term administrations of delta-9-tetrahydrocannabinol modulate major gut metabolomic regulatory pathways in C57BL/6...

1. Hill, K. P. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. Jama 313, 2474–2483 (2015). 2. Koppel, B. S. et al. Systematic review: Efficacy and safety of medical...

Positive functional synergy of structurally integrated artificial protein dimers assembled by Click chemistry

Click chemistry interface sites We surmised that areas of a protein’s surface that are compatible in terms of association are more likely to generate an integrated structure through the formation of mutually compatible non-covalent interactions....

UK VC Medicxi Closes Third Fund with €400M to Boost European Biotech

The UK-based venture capital investment firm Medicxi has closed its third fund, totaling €400M, to nurture early- and late-stage healthcare biotech companies in Europe. The firm will begin investing in the first beneficiary companies of...

Many of the deadliest cancers receive the least amount of research funding

‘Embarrassing’ or stigmatized cancers like lung and liver are underfunded Credit: Northwestern University Poorly funded cancers: colon, endometrial, liver and bile duct, cervical, ovarian, pancreatic and lung Well-funded cancers: breast, pediatric, leukemia and lymphoma All...

Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs

The Danish biotech Genmab has made a big splash on the Nasdaq, raising a €450M ($506M) IPO to fuel its antibody drug programs in cancer, autoimmune diseases, and more. This IPO is one of the...

New Analysis Finds Vast Majority of Dietary Supplements to have no Effect on Heart...

A massive new analysis published on 8 July in the Annals of Internal Medicine, which included findings from 277 randomised clinical trials using 24 different interventions (and a total of 992,129 subjects from around...

Stay connected

43,285FollowersFollow
13,550SubscribersSubscribe

Recent posts

Random article